These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 25848861)

  • 1. Multigene prognostic tests in breast cancer: past, present, future.
    Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
    Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gene signatures for breast cancer, clinical utility and therapeutic applications].
    Vargas-Aguilar VM; Arroyo-Alvarez K
    Rev Med Inst Mex Seguro Soc; 2018; 56(2):180-185. PubMed ID: 29906029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
    Ma CX; Bose R; Ellis MJ
    Adv Exp Med Biol; 2016; 882():125-54. PubMed ID: 26987533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
    JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
    Nicolini A; Ferrari P; Duffy MJ
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular tests as prognostic factors in breast cancer.
    van de Vijver MJ
    Virchows Arch; 2014 Mar; 464(3):283-91. PubMed ID: 24487789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
    Duffy MJ; Harbeck N; Nap M; Molina R; Nicolini A; Senkus E; Cardoso F
    Eur J Cancer; 2017 Apr; 75():284-298. PubMed ID: 28259011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
    Bertucci F; Finetti P; Viens P; Birnbaum D
    Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification in early breast cancer in premenopausal and postmenopausal women: integrating genomic assays with clinicopathological features.
    Sestak I
    Curr Opin Oncol; 2019 Jan; 31(1):29-34. PubMed ID: 30299292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.
    Khan SS; Karn T; Symmans WF; Rody A; Müller V; Holtrich U; Becker S; Pusztai L; Hatzis C
    Breast Cancer Res Treat; 2015 Feb; 149(3):789-97. PubMed ID: 25651779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commercialized multigene predictors of clinical outcome for breast cancer.
    Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
    Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
    Kwon MJ
    Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
    Colomer R; Aranda-López I; Albanell J; García-Caballero T; Ciruelos E; López-García MÁ; Cortés J; Rojo F; Martín M; Palacios-Calvo J
    Clin Transl Oncol; 2018 Jul; 20(7):815-826. PubMed ID: 29273958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.